Klaria Pharma Holding AB (FRA:6FN) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Klaria Pharma Holding AB LT-Debt-to-Total-Asset?

Klaria Pharma Holding AB FRA:6FN +3.51% 28 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 28/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Klaria Pharma Holding AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Klaria Pharma Holding AB's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

Klaria Pharma Holding AB (FRA:6FN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Klaria Pharma Holding AB LT-Debt-to-Total-Asset Related Terms

Klaria Pharma Holding AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB LT-Debt-to-Total-Asset Chart

Klaria Pharma Holding AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

0.01

0.00

Klaria Pharma Holding AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

28GF Score

Klaria Pharma Holding AB FRA:6FN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Klaria Pharma Holding AB LT-Debt-to-Total-Asset Calculation

Klaria Pharma Holding AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	3.746
	=	0.00

Klaria Pharma Holding AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	2.786
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Klaria Pharma Holding AB (FRA:6FN) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Klaria Pharma Holding AB and its competitors.

Is Klaria Pharma Holding AB's LT-Debt-to-Total-Asset too high?

Klaria Pharma Holding AB's current LT-Debt-to-Total-Asset is 0.00. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Klaria Pharma Holding AB's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Klaria Pharma Holding AB's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Klaria Pharma Holding AB stock overvalued right now?

Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 106.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 106.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €0.03 vs. price of €0.06 (106.3% above fair value)
GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Klaria Pharma Holding AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XSAT:ODI XSAT:PMED OSTO:GABA OSTO:ERMA OSTO:MOB OSTO:CINPHA OSTO:ENZY XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges KLAR:Sweden

Address Virdings Alle 2, Uppsala, CHE, 754 50

Website https://www.klaria.com

Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.

28GF Score

Get the complete analysis for FRA:6FN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06

Price

€0.03

GF Value

View FRA:6FN Analysis

See LT-Debt-to-Total-Asset data for all stocks →